CSBTF (Kuros Biosciences) Total Payout Ratio : 0.11 (As of Dec. 14, 2024)

View and export this data going back to . Start your Free Trial

What is Kuros Biosciences Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Kuros Biosciences's current Total Payout Ratio is 0.11.

Kuros Biosciences Total Payout Ratio Historical Data

The historical data trend for Kuros Biosciences's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Total Payout Ratio Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

1.21

1.54

0.38

0.04

Kuros Biosciences Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-0.75

Competitive Comparison of Kuros Biosciences's Total Payout Ratio

For the Medical Devices subindustry, Kuros Biosciences's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences's Total Payout Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Total Payout Ratio falls into.

Kuros Biosciences Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Kuros Biosciences's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.579	+	0)	/	-15.434
	=	0.04

Kuros Biosciences's Total Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.925	+	0)	/	1.226
	=	-0.75

Kuros Biosciences Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (OTCPK:CSBTF) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

KURNz:UK 0RHR:UK KURN:Switzerland

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.